Torrent Pharma Q1 revenue jumps 55% after JB Pharma acquisition; PAT rises 3.3%
Torrent Pharmaceuticals reported Q1 FY27 revenue of ₹4,921 crore, up 55% year-on-year, aided by JB Pharma. Profit after tax rose 3.3% to ₹566 crore as integration, depreciation and higher finance costs weighed on earnings. India revenue grew 19%.
Torrent Pharma’s FY27 first-quarter revenue rose 55% following JB Pharma’s acquisition, while PAT grew 3.3% as integration, depreciation and finance costs increased. India revenue rose 19%, with Torrent leading cardiac therapies and holding 36% of generic Semaglutide.
Why this matters
The result follows a recent signal that Torrent Pharma's Q1 FY27 revenue rose 55% and profit rose about 3% as JB Pharma-related costs weighed, reinforcing acquisition-led sales growth alongside earnings pressure.
Retail-company signals are accelerating, up 252940% quarter-on-quarter.